[1]常丙林.恶性脑胶质瘤组织MGMT的表达及临床意义[J].中国临床神经外科杂志,2017,(03):171-173.[doi:10.13798/j.issn.1009-153X.2017.03.015]
 CHANG Bing-lin..Expression of MGMT in malignant glioma tissues and its clinical meaning[J].,2017,(03):171-173.[doi:10.13798/j.issn.1009-153X.2017.03.015]
点击复制

恶性脑胶质瘤组织MGMT的表达及临床意义 ()
分享到:

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
期数:
2017年03期
页码:
171-173
栏目:
论著
出版日期:
2017-03-20

文章信息/Info

Title:
Expression of MGMT in malignant glioma tissues and its clinical meaning
文章编号:
1009-153X(2017)03-0171-03
作者:
常丙林
455000 河南,安阳地区医院神经外科
Author(s):
CHANG Bing-lin.
Department of Neurosurgery, Hospital of Anyang District, Anyang 455000, China
关键词:
恶性脑胶质瘤O6-甲基鸟嘌呤-DNA甲基转移酶基因表达预后相关性
Keywords:
Malignant gliomas MGMT Expression level Prognosis Relationship
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2017.03.015
文献标志码:
A
摘要:
目的 探讨恶性脑胶质瘤组织O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)的表达与临床意义。方法 选取2012年11月至2014年4月收治的166例恶性脑胶质瘤患者为研究对象,分为>50岁组86例,≤50岁组80例,采用免疫组化技术检测所有肿瘤组织MGMT蛋白表达情况。比较不同年龄患者MGMT蛋白表达情况及MGMT表达水平与患者生存时间的相关性。结果 166例中,MGMT阴性表达82例,弱阳性表达40例,强阳性表达42例;MGMT阴性表达、弱阳性表达、强阳性表达患者生存时间分别为(24.15±3.27)、(17.35±3.16)、(13.25±1.34)个月,两两比较差异具有统计学意义(P<0.05)。结论 恶性脑胶质瘤组织MGMT表达水平与患者预后存在一定相关性,MGMT表达水平越高,患者预后越差。
Abstract:
Objective To investigate the expression of 06-methyl guanine-DNA methyltransferase (MGMT) in malignant gliomas and its clinical meaning. Methods The MGMT protein expression was determined by immunohistochemiscal technique in 166 specimens of malignant gliomas tissues derived from 166 patients treated in our hospital from November, 2012 to April, 2014. The relationship between the MGMT protein expression level with patients' age and survival time was analyzed. Results The survival time [(24.15±3.27) months] was significantly longer in MGMT negative expression group than that [(17.35±3.16) months] in MGMT positive expression group (P<0.01), which was significantly longer than that [(13.25±1.34) months] in MGMT strongly positive expression group (P<0.01). Conclusions The expression level of MGMT in the malignant gliomas tissues is correlated with the patients' prognoses. High expression level of MGMT in the malignant gliomas tissues suggests bad prognosis in the patients with malignant gliomas.

参考文献/References:

[1] 马继伟,赵新利,庞长河,等. 经侧裂入路岛叶胶质瘤的显 微外科治疗[J]. 中华显微外科杂志,2015,38(5):486- 489.
[2] 文 军,王向宇,王立江,等. 替尼泊甙联合司莫司汀治疗 脑胶质瘤疗效与MGMT表达关系的研究[J]. 中华神经医 学杂志,2010,9(1):47-50.
[3] 张文学,孙 健,曹永珍,等. 采用不同边界适形调强放疗 结合替莫唑胺化疗治疗恶性胶质瘤的近期疗效观察[J]. 中华医学杂志,2015,95(31):2522-2525.
[4] 郝振强,卢培刚,袁绍纪,等. MGMT表达检测指导恶性脑 胶质瘤个体化化疗研究[J]. 中华神经外科疾病研究杂 志,2013,12(3):262-264.
[5] Milena C, Marina NN, Matija S, et al. The role of MGMT testing in clinical practice: a report of the association for molecular pathology [J]. J Mol Diagn, 2013, 15(5): 539-555.
[6] 张国锋,胡卫星,顾培元,等. 脑干桥延部肿瘤显微外科手 术治疗及并发症的防治[J]. 中华神经外科杂志,2013,29 (4):367-369.
[7] 吴 涛,刘 胜,王 诚,等. 塞来昔布影响胶质瘤细胞增 殖及运动、侵袭的生物特性研究[J]. 中国临床神经外科 杂志,2011,16(5):288-292.
[8] 杨洪宽,毛 峰,万 锋,等. LRIG3基因对脑胶质瘤细胞 系U87和U251的细胞周期、侵袭性和凋亡的影响[J]. 中 国临床神经外科杂志,2011,16(4):220-223.
[9] 唐天友,许莹莹,王建设,等. 人脑胶质瘤组织MGMT和 EGFR及Ki-67表达临床意义分析[J]. 中华肿瘤防治杂 志,2013,20(11):840-844.
[10] 许洪升,张俊英,岳伟英,等. 脑胶质瘤MGMT表达与体 外药敏相关性及其临床意义[J]. 中国临床神经外科杂 志,2007,12(5):263-266.

相似文献/References:

[1]李建明.三维适形放疗联合替莫唑胺化疗对恶性脑胶质瘤术后残留的疗效分析[J].中国临床神经外科杂志,2017,(05):316.[doi:10.13798/j.issn.1009-153X.2017.05.011]
 LI Jian-ming..Short-term curative effect and factors related to prognosis of three dimensional conformal radiotherapy combined with temozolomide chemotherapy on residual malignant gliomas after surgery[J].,2017,(03):316.[doi:10.13798/j.issn.1009-153X.2017.05.011]
[2]赵宇航 王泽芬 徐成仕 李 凯 李志强.人脑胶质瘤IDH1突变状态与MGMT启动子甲基化、P53和TERT突变相关性[J].中国临床神经外科杂志,2018,(05):339.[doi:10.13798/j.issn.1009-153X.2018.05.011]
 ZHAO Yu-hang,WANG Ze-fen,XU Cheng-shi,et al.Correlativity of IDH1 mutation with MGMT promoter methylation and P53 and TERT mutations in gliomas[J].,2018,(03):339.[doi:10.13798/j.issn.1009-153X.2018.05.011]
[3]张国臣 常玉喜 韩 磊 徐 欣 赵 明 陈忠平.新诊断胶质瘤MGMT基因启动子甲基化水平定量分析[J].中国临床神经外科杂志,2020,(06):374.[doi:10.13798/j.issn.1009-153X.2020.06.012]
 ZHANG Guo-chen,CHANG Yu-xi,HAN Lei,et al.Quantitative analysis of methylation level of MGMT gene promoter in newly diagnosed glioma[J].,2020,(03):374.[doi:10.13798/j.issn.1009-153X.2020.06.012]

更新日期/Last Update: 2017-03-25